1 / 8

ARMYDA-3 Trial: Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery

This trial evaluated the effects of atorvastatin on post-operative atrial fibrillation in patients undergoing elective cardiac surgery. Atorvastatin reduced the occurrence of atrial fibrillation and resulted in shorter hospitalization duration. Presented at the ACC 2006.

mtully
Télécharger la présentation

ARMYDA-3 Trial: Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARMYDA-3 Trial Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac SurgeryTrial Presented at The American College of Cardiology Scientific Sessions March 2006 Presented by Dr. Giuseppe Patti

  2. ARMYDA-3 Trial: Background • The objective of this trial was to evaluate the effects of treatment with atorvastatin versus placebo on the occurrence of post-operative atrial fibrillation among patients undergoing elective cardiac surgery • Statin therapy has been shown to be associated with reductions in ischemic events following acute coronary syndromes • It is hypothesized that statin therapy will reduce incidences of post-operative atrial fibrillation because of its anti-inflammatory effects Presented at ACC 2006

  3. ARMYDA-3 Trial: Study Design 200 patientsundergoing elective cardiac surgery were randomized to either atorvastatin or placebobeginning 7 days before the operation Placebo-controlled. Randomized. Blinded 31% female, mean age 66 years, mean follow-up 30 days Patients had no previous history of statin treatment or atrial fibrillation Baseline EF was 52%; 97% of patients had multi-vessel disease Atorvastatin 40 mg/day n=101 Placebo n=99 C-reactive protein (CRP) levels measured prior to surgery and every 24 hours until discharge • Primary Endpoint: Post-operative occurrence of atrial fibrillation lasting >5 minutes through discharge Presented at ACC 2006

  4. ARMYDA-3 Trial: Primary Endpoint Post-operative occurrence of atrial fibrillation (%) p=0.003 • Post-operative occurrence of atrial fibrillation occurred less frequently in the atorvastatin group than in the placebo group (35% vs 57%; p=0.003) % occurrence AF Presented at ACC 2006

  5. ARMYDA-3 Trial: Clinical Results Mean Duration of Hospitalization (days) p=0.001 • Duration of hospitalization was shorter in the atorvastatin group than in the placebo group (6.3 vs 6.9 days; p=0.001) Presented at ACC 2006

  6. ARMYDA-3 Trial: Clinical Results Time of onset of atrial fibrillation from surgery (Hours) p=NS Duration of arrhythmic episodes (Hours) p=NS • There was no difference in time of onset of atrial fibrillation from surgery or duration of arrhythmic episodes • Through 30 days there were 2 deaths in each group, 3 MIs in each group, no repeat revascularizations, and 1 stroke in the placebo group Presented at ACC 2006

  7. ARMYDA-3 Trial: Limitations • The rate of post-operative fibrillation was relatively high due to the definition of the event which only required 5 minutes of atrial fibrillation to meet the endpoint criteria • A larger study would be needed to confirm these findings Presented at ACC 2006

  8. ARMYDA-3 Trial: Summary • Treatment with atorvastatin was associated with a reduction in the occurrence of post-operative atrial fibrillation compared with placebo in patients undergoing elective cardiac surgery • Patients in the atorvastatin group had a significantly shorter duration of hospitalization (6.3 days vs 6.9 days, p=0.001) but no difference was seen between the groups in time of onset of atrial fibrillation or duration of arrhythmic episodes • Peak post-operative CRP levels were significantly lower in patients without atrial fibrillation than in patients with atrial fibrillation (p<0.025) regardless of study drug randomization group Presented at ACC 2006

More Related